Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

26.06.15	Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action (GlobeNewswire)
18.06.15	Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg (GlobeNewswire)
18.06.15	Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day (GlobeNewswire)
16.06.15	Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery (GlobeNewswire)
13.06.15	Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML (GlobeNewswire)
13.06.15	Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control (GlobeNewswire)
12.06.15	Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma (GlobeNewswire)
12.06.15	Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia (GlobeNewswire)
12.06.15	Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients (GlobeNewswire)
11.06.15	Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder (GlobeNewswire)
11.06.15	Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and soles (GlobeNewswire)
10.06.15	Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients (GlobeNewswire)
02.06.15	Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions (GlobeNewswire)
01.06.15	Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma (GlobeNewswire)
01.06.15	Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs (GlobeNewswire)
31.05.15	Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma (GlobeNewswire)
27.05.15	Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA (GlobeNewswire)
21.05.15	Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors (GlobeNewswire)
20.05.15	Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 (GlobeNewswire)
08.05.15	Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC (GlobeNewswire)
27.04.15	Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL (GlobeNewswire)
23.04.15	Novartis erzielt im ersten Quartal[1] Umsatzsteigerungen (kWk), deutlich höhere Margen (kWk) und beachtliche Innovationen - jetzt mit einem stärker fokussierten Portfolio (GlobeNewswire)
23.04.15	Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio (GlobeNewswire)
21.04.15	Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients (GlobeNewswire)
16.04.15	Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg (GlobeNewswire)
16.04.15	Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States (GlobeNewswire)
15.04.15	Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients (GlobeNewswire)
13.04.15	Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians (GlobeNewswire)
30.03.15	Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload (GlobeNewswire)
30.03.15	Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group (GlobeNewswire)
21.03.15	Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients (GlobeNewswire)
20.03.15	New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients (GlobeNewswire)
17.03.15	Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer (GlobeNewswire)
17.03.15	Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer (GlobeNewswire)
13.03.15	Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin (GlobeNewswire)
13.03.15	Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin (GlobeNewswire)
06.03.15	FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz (GlobeNewswire)
02.03.15	Novartis gibt Abschluss von Transaktionen mit GSK bekannt (GlobeNewswire)
02.03.15	Novartis announces completion of transactions with GSK (GlobeNewswire)
27.02.15	Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration (GlobeNewswire)
27.02.15	Novartis shareholders approve all resolutions proposed by Novartis Board of Directors (GlobeNewswire)
27.02.15	Aktionäre genehmigen alle Anträge des Verwaltungsrats von Novartis (GlobeNewswire)
27.02.15	Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib (GlobeNewswire)
23.02.15	Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma (GlobeNewswire)
13.02.15	Novartis' heart failure medicine LCZ696 granted FDA priority review (GlobeNewswire)
02.02.15	Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief (GlobeNewswire)
28.01.15	Novartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera (GlobeNewswire)
27.01.15	Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses (GlobeNewswire)
23.01.15	Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US (GlobeNewswire)
23.01.15	Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	73.52	1.69 %	K V
ABB	51.72	0.90 %	K V
Part Grp Hldg	1’310.50	0.85 %	K V
CieFinRichemont	128.70	0.82 %	K V
Sika	237.60	0.76 %	K V
Swisscom	507.00	-0.29 %	K V
Swiss Life Hldg	688.00	-0.35 %	K V
Kuehne+Nagel Int	212.30	-0.52 %	K V
Givaudan	3’868.00	-1.02 %	K V
Novartis	91.32	-1.83 %	K V

mehr

09:28		Freundlicher Handel in Frankfurt: TecDAX legt zum Start zu
09:28		STOXX-Handel: Euro STOXX 50 zum Start auf grünem Terrain
09:28		Mittwochshandel in Frankfurt: LUS-DAX beginnt Sitzung mit Gewinnen
09:28		SPI-Handel aktuell: SPI startet in der Verlustzone
09:28		Optimismus in Europa: STOXX 50 zum Start im Aufwind
09:28		LSE-Handel FTSE 100 startet im Minus